321 related articles for article (PubMed ID: 34281283)
1. Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.
Longo F; Piolatto A; Ferrero GB; Piga A
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281283
[TBL] [Abstract][Full Text] [Related]
2. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
[TBL] [Abstract][Full Text] [Related]
3. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
Musallam KM; Rivella S; Taher AT
Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
[No Abstract] [Full Text] [Related]
4. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
[TBL] [Abstract][Full Text] [Related]
5. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
[TBL] [Abstract][Full Text] [Related]
6. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
Camaschella C; Nai A
Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
[TBL] [Abstract][Full Text] [Related]
7. The Role of Iron in Benign and Malignant Hematopoiesis.
Sinha S; Pereira-Reis J; Guerra A; Rivella S; Duarte D
Antioxid Redox Signal; 2021 Aug; 35(6):415-432. PubMed ID: 33231101
[No Abstract] [Full Text] [Related]
8. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
[TBL] [Abstract][Full Text] [Related]
9. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
10. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
11. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
13. Luspatercept to treat β-thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2020 Jul; 56(7):447-458. PubMed ID: 32648855
[TBL] [Abstract][Full Text] [Related]
14. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
[TBL] [Abstract][Full Text] [Related]
15. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.
Arlet JB; Ribeil JA; Guillem F; Negre O; Hazoume A; Marcion G; Beuzard Y; Dussiot M; Moura IC; Demarest S; de Beauchêne IC; Belaid-Choucair Z; Sevin M; Maciel TT; Auclair C; Leboulch P; Chretien S; Tchertanov L; Baudin-Creuza V; Seigneuric R; Fontenay M; Garrido C; Hermine O; Courtois G
Nature; 2014 Oct; 514(7521):242-6. PubMed ID: 25156257
[TBL] [Abstract][Full Text] [Related]
16. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
17. Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.
Breda L; Rivella S
Hematol Oncol Clin North Am; 2014 Apr; 28(2):375-86. PubMed ID: 24589272
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
20. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
